XTL Biopharmaceutica Ownership
| XTLB Stock | USD 2.10 0.22 11.70% |
Shares in Circulation | First Issued 2004-03-31 | Previous Quarter 544.9 M | Current Value 544.9 M | Avarage Shares Outstanding 30.2 M | Quarterly Volatility 118.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
XTL |
XTL Stock Ownership Analysis
The book value of the company was at this time reported as 0.01. The company recorded a loss per share of 0.03. XTL Biopharmaceuticals last dividend was issued on the 10th of February 2017. The entity had 1:5 split on the 10th of February 2017. XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel. Xtl Biopharma is traded on NASDAQ Exchange in the United States. For more information please call Shlomo Shalev at 972 3 611 6600 or visit https://www.xtlbio.com.Besides selling stocks to institutional investors, XTL Biopharmaceutica also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different XTL Biopharmaceutica's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align XTL Biopharmaceutica's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
XTL Biopharmaceutica Quarterly Liabilities And Stockholders Equity |
|
About 5.0% of XTL Biopharmaceuticals Ltd are currently held by insiders. Unlike XTL Biopharmaceutica's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against XTL Biopharmaceutica's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of XTL Biopharmaceutica's insider trades
XTL Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as XTL Biopharmaceutica is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading XTL Biopharmaceuticals Ltd backward and forwards among themselves. XTL Biopharmaceutica's institutional investor refers to the entity that pools money to purchase XTL Biopharmaceutica's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Noked Israel Ltd | 2024-09-30 | 198.9 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 26.5 K | Rhumbline Advisers | 2024-09-30 | 6.5 K | Bnp Paribas Arbitrage, Sa | 2024-06-30 | 0.0 | Ubs Group Ag | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 |
XTL Biopharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific XTL Biopharmaceutica insiders, such as employees or executives, is commonly permitted as long as it does not rely on XTL Biopharmaceutica's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases XTL Biopharmaceutica insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
XTL Biopharmaceutica Outstanding Bonds
XTL Biopharmaceutica issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. XTL Biopharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most XTL bonds can be classified according to their maturity, which is the date when XTL Biopharmaceuticals Ltd has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| XEL 46 01 JUN 32 Corp BondUS98388MAD92 | View | |
| XEL 235 15 NOV 31 Corp BondUS98388MAC10 | View | |
| XEL 175 15 MAR 27 Corp BondUS98388MAB37 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| XCEL ENERGY INC Corp BondUS98389BAU44 | View | |
| XCEL ENERGY INC Corp BondUS98389BAV27 | View | |
| XCEL ENERGY INC Corp BondUS98389BAR15 | View | |
| XCEL ENERGY INC Corp BondUS98389BAN01 | View |
XTL Biopharmaceutica Corporate Filings
6K | 19th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 30th of April 2024 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether XTL Biopharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of XTL Biopharmaceutica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xtl Biopharmaceuticals Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xtl Biopharmaceuticals Ltd Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XTL Biopharmaceuticals Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XTL Biopharmaceutica. If investors know XTL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about XTL Biopharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Earnings Share (0.03) | Return On Assets (0.14) | Return On Equity (0.13) |
The market value of XTL Biopharmaceuticals is measured differently than its book value, which is the value of XTL that is recorded on the company's balance sheet. Investors also form their own opinion of XTL Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is XTL Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XTL Biopharmaceutica's market value can be influenced by many factors that don't directly affect XTL Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between XTL Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if XTL Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XTL Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.